Related by context. All words. (Click for frequent words.) 73 LEP ETU 69 elotuzumab 69 oral prodrug 68 IMA# 68 IL# PE#QQR 68 oral picoplatin 68 Cintredekin Besudotox 67 cintredekin besudotox 67 LE SN# 67 CR# vcMMAE 67 TELINTRA 66 huC# DM4 66 alvespimycin 66 JAK2 inhibitor 66 tolevamer 66 IL# PE 66 AEG# 66 Troxatyl 66 JAK inhibitor 65 PLK1 SNALP 65 Amplimexon 65 MAGE A3 ASCI 65 CINTREDEKIN BESUDOTOX 65 tezampanel NGX# 65 HGS ETR1 65 CCR9 antagonist 65 TLK# 65 Alocrest 65 torezolid phosphate 65 CCX# 65 GRN# 65 Archexin 65 INCB# [001] 65 Bezielle 65 cediranib 65 phase IIa clinical 64 Panzem R NCD 64 MEK inhibitors 64 trastuzumab DM1 T DM1 64 TOCOSOL Camptothecin 64 Factor VIIa 64 BrachySil TM 64 systemic immunosuppressive drugs 64 talactoferrin 64 phase IIb clinical 64 ELACYT 64 PRT# 64 FluCide 64 DPX Survivac 64 Zingo TM 64 ONCONASE R 64 Zemiva TM 64 Aflibercept 64 Xanafide 64 CBLC# 64 Dalbavancin 64 docetaxel Taxotere ® 64 Genasense ® 64 Hepatocellular Carcinoma HCC 64 SinuNase TM 64 neratinib 64 volociximab 64 evaluating tivozanib 64 Cloretazine R VNP#M 64 TOCOSOL Paclitaxel 64 Squalamine 64 riociguat 64 budesonide foam 64 Tyrima 64 RhuDex ® 64 forodesine 64 forodesine hydrochloride 64 Phase Ib study 64 ZOLINZA 64 HQK 64 PNP inhibitor 64 OvaRex R 64 IRX 2 64 CYT# potent vascular disrupting 63 ganetespib 63 BAY #-# 63 Zenvia ™ 63 erlotinib Tarceva ® 63 PEG SN# 63 ZK EPO 63 HGS ETR2 63 Octreolin 63 ApoB SNALP 63 zanolimumab 63 Aganocide 63 DCVax R 63 PDE4 inhibitor 63 Traficet EN 63 vidofludimus 63 GSK# [001] 63 Telatinib 63 mertansine 63 Fodosine 63 peripherally acting 63 OMNARIS HFA 63 Zenvia TM 63 anticancer compound 63 ALN TTR 63 OncoVEX GM CSF 63 OncoVEX 63 nalbuphine ER 63 receptor tyrosine kinase inhibitor 63 Bicifadine 63 AeroLEF TM 63 ATL# [002] 63 SinuNase 63 Rescula 63 Sym# 63 Solazed TM 63 PrevOnco 63 ruxolitinib 63 Fibrillex TM 63 OXi# 63 TKM ApoB 63 Ophena TM 63 Aurexis 63 elacytarabine 63 Neuradiab 63 Aplidin 63 #D#C# 63 Phase #b/#a clinical 63 metastatic RCC 63 Pralatrexate 63 HGS ETR1 mapatumumab 63 docetaxel Taxotere R 63 sorafenib Nexavar 63 pseudobulbar affect PBA 63 HSP# inhibitor 63 INT# [002] 63 metaglidasen 63 tanespimycin 63 HGS# 63 small molecule tyrosine 63 PRECISE trial 63 Onalta ™ 63 palifermin 63 PEGylated Fab fragment 63 faropenem 63 Prednisporin TM 63 DDP# 62 TroVax ® 62 bosutinib 62 XP# XP# 62 deforolimus 62 Cloretazine ® 62 PSN# [002] 62 PXD# 62 RSD# oral 62 ALN TTR# 62 HCD# [002] 62 KRN# 62 SIRT1 activators 62 Aptivus ® 62 Proxinium TM 62 YONDELIS 62 BEMA TM Fentanyl 62 relapsed SCLC 62 EndoTAG TM -1 62 NP2 Enkephalin 62 ALN PCS 62 systemically administered 62 cystinosis patients 62 superficial bladder cancer 62 Chemophase 62 EDEMA3 trial 62 Gemzar ® 62 PDE4 inhibitors 62 dextromethorphan quinidine 62 Tezampanel 62 XL# anticancer compounds 62 Neurodex 62 preclinically 62 Surfaxin LS 62 MyVax R 62 Allovectin 7 R 62 E2F Decoy 62 Romidepsin 62 recurrent glioblastoma 62 Tamibarotene 62 oral methylnaltrexone 62 Pruvel 62 Diamyd ® 62 antitumor effect 62 alkylating agent 62 SAR# [004] 62 Kamada AAT 62 Altastaph 62 pharmacokinetic interactions 62 otelixizumab 62 PEGylated 62 Insegia 62 Ereska 62 Phase IIb clinical trials 62 ocrelizumab 62 eltrombopag 62 EFAPROXYN 62 aflibercept VEGF Trap 62 TELCYTA 62 AERx ® 62 Dacogen injection 62 MyVax ® 62 Personalized Immunotherapy 62 MOZOBIL 62 NV1FGF 62 pertuzumab 62 acyclovir Lauriad R 62 EP #R 62 MKC# MT 62 MNTX 62 PROCHYMAL 62 CoFactor 62 dacetuzumab 62 lomitapide 62 class mGluR5 inhibitor 62 L BLP# 62 CIMZIA TM certolizumab pegol 62 confirmatory Phase III 62 SEPET TM 62 Dyloject TM 62 PANVAC VF 62 Dapagliflozin 62 HuLuc# 62 BRAF inhibitor 62 GW# [003] 62 hypoxia activated prodrug 62 investigational monoclonal antibody 62 Xcytrin R 62 synthetic retinoid 62 bardoxolone 61 R#/MEM # 61 NEUMUNE 61 non nucleoside 61 incyclinide 61 Onconase 61 Gliadel Wafer 61 AQ4N 61 proteasome inhibitor 61 liposomal formulation 61 FUSILEV enhances 61 phase IIb III 61 Zybrestat 61 Phase IIb trials 61 Aurora Kinase 61 Phenoptin 61 Octreotide 61 ALK inhibitor 61 PDX pralatrexate 61 IAP inhibitors 61 Preclinical studies suggest 61 subcutaneous formulation 61 tezampanel 61 sorafenib tablets 61 Fibrin Pad 61 Azedra 61 lumiliximab 61 cannabinor 61 UPLYSO 61 oral anticancer 61 dexanabinol 61 Intravenous CP 61 6R BH4 61 Trofex 61 Maribavir 61 TYZEKA 61 CEQ# 61 orally administered inhibitor 61 XL# XL# XL# XL# 61 Linjeta TM 61 antibody MAb 61 Microplasmin 61 Allovectin 7 61 docetaxel Taxotere 61 Aurora kinase inhibitor 61 GLP toxicology studies 61 PGL# 61 Androxal TM 61 Methylnaltrexone 61 Advaxis Phase 61 orally dosed 61 octreotide implant 61 GALNS 61 OHR/AVR# 61 Ophena 61 Elotuzumab 61 investigational humanized monoclonal antibody 61 NovaBay Aganocide compounds 61 adipiplon 61 acetonide FA 61 HspE7 61 Phenserine 61 Phase Ib 61 XL# XL# 61 NGX# 61 pradefovir 61 HuMax EGFr 61 Azedra TM 61 gefitinib Iressa 61 KIACTA ™ 61 reslizumab 61 lesinurad 61 Proellex TM 61 LBH# 61 virus HCV protease inhibitor 61 recurrent glioblastoma multiforme 61 Poly ICLC 61 BRAF inhibitors 61 velafermin 61 Pagoclone 61 CB2 selective receptor agonist 61 Phase 2a clinical trials 61 fosbretabulin 61 Panzem R 61 successfully commercialize Iluvien 61 ONCONASE 61 MAP# 61 #I TM# 61 Bortezomib 61 enzastaurin 61 cangrelor 61 Cethrin 61 amrubicin 61 p# inhibitor 61 Panzem NCD 61 DOS# 61 StemEx R 61 CCX# B 61 registrational 61 Genz # 61 AP# [003] 61 KNS # 61 nanoviricide drug 61 SERMs 61 CRMD# 61 Mepact 61 visilizumab 61 TRO# 61 dasatinib Sprycel ® 61 evaluating picoplatin 61 Relivar 61 icatibant 61 colorectal liver metastases 61 Sudhir Agrawal D.Phil 61 RGB # 61 MEK inhibitor RDEA# 61 Cardio Vascu Grow 61 cancer immunotherapies 61 indibulin 61 EVIZON TM squalamine lactate 61 antiangiogenic agents 61 candidate deforolimus 61 ACTEMRA TM 61 metastatic colorectal 61 AKT inhibitor 61 dirucotide 61 Pazopanib 61 diabetic gastroparesis 61 Novolimus 61 MAXY G# 60 oxymorphone ER 60 systemic RNAi therapeutic 60 Veronate 60 modified glutathione analog 60 Tarceva TM 60 Perifosine 60 lucinactant 60 compound INCB# 60 trastuzumab Herceptin R 60 novel VDA molecule 60 GSK# [002] 60 HER2 positive metastatic breast 60 trastuzumab DM1 60 dasatinib Sprycel 60 TransVax ™ 60 GVAX ® 60 cetuximab Erbitux R 60 ulimorelin 60 mRCC 60 phase IIb study 60 Panzem 60 maximally tolerated dose 60 vinorelbine tartrate 60 Phase III confirmatory 60 MGCD# [001] 60 SNT MC# 60 recurrent GBM 60 Sphingomab 60 Telintra 60 Zemplar Capsules 60 Targretin 60 Lenocta TM 60 HDAC Inhibitor 60 refractory AML 60 blood clot dissolver 60 Anavex #-# 60 Thiovir 60 targeted antifolate 60 celgosivir 60 assessing T DM1 60 IMC #B 60 Saforis 60 dimebon latrepirdine 60 lapatinib Tykerb 60 catheter occlusion 60 adjuvant colon cancer 60 Cerashield 60 BiovaxID TM 60 tremelimumab 60 multitargeted 60 BiTE antibody 60 oral ridaforolimus 60 delafloxacin 60 eprotirome 60 Atiprimod 60 Eculizumab 60 Dasatinib 60 OMS#HP 60 URG# 60 Familial Adenomatous Polyposis FAP 60 CIMZIA TM 60 SinuNase ™ 60 Allovectin 7 ® 60 obatoclax 60 REOLYSIN ® 60 IIa trial 60 radiation sensitizer 60 relapsed leukemia 60 ADP receptor antagonist 60 eTag assays 60 Stimuvax R 60 talabostat 60 nonclinical studies 60 HCV protease inhibitors 60 INCB# [003] 60 teduglutide 60 clevidipine 60 Quinamed 60 CINQUIL 60 Exelixis compounds 60 treat chronic sinusitis 60 custirsen 60 recurrent NSCLC 60 lexidronam injection 60 PEP# [003] 60 Seliciclib 60 interferon gamma 1b 60 Fx #A 60 faropenem medoxomil 60 CLORETAZINE TM VNP#M 60 JAK1 60 intravenous formulations 60 ponatinib 60 samalizumab 60 Phase #/#a 60 NOX E# 60 intranasal formulation 60 FOLOTYN ® 60 CVT E# 60 leading oral taxane 60 R sorafenib tablets 60 protein kinase inhibitor 60 CA4P 60 axitinib 60 ZACTIMA 60 Pafuramidine 60 evaluating satraplatin 60 Ridaforolimus 60 Golimumab 60 Hyphanox 60 Cloretazine R 60 Pimavanserin 60 pralatrexate 60 PI3K/Akt pathway inhibitor 60 diabetic neuropathic pain 60 Afatinib 60 including eniluracil ADH 60 anti angiogenic agents 60 TG# [003] 60 IoGen 60 Cannabinor 60 phase IIa 60 methylnaltrexone 60 ostarine 60 anticancer therapy 60 CIPN 60 CA9 SCAN 60 Phase Ib clinical trials 60 AzaSite Plus 60 CYC# 60 CCR5 mAb 60 Nuvion 60 ISTODAX 60 RNAi therapeutic targeting 60 Aganocide ® 60 ENMD # 60 Darusentan 60 initiate Phase 1b 60 cobiprostone 60 siRNA therapeutics 60 PROVENGE sipuleucel T 60 Hedgehog antagonist 60 orBec 60 BLA filing 60 tubulin inhibitor 60 Akt inhibitor 60 refractory CLL 60 OvaRex ® MAb 60 invasive candidiasis 60 Elocalcitol 60 epigenetic therapies 60 Mipomersen 60 SUTENT ® 60 refractory gout 60 GEM OS2 60 Iluvien ® 60 VEGFR2 inhibitor 60 Vaxfectin TM 60 Phase #/#a trial 60 oxaliplatin Eloxatin 60 XmAb# 60 herpetic keratitis 60 EOquin 60 oral Janus kinase 60 pimecrolimus 60 Tavocept 60 Lixivaptan 60 neovascular diseases 60 nucleoside analog 60 Neuvenge 60 novel histone deacetylase 59 DAVANAT 59 CIMZIA ™ 59 RNA antagonist 59 Tesetaxel 59 phase IIb 59 G#DT 59 Smac mimetic 59 ancrod 59 unresectable stage 59 mapatumumab 59 Solazed 59 Liposomal 59 Entereg R 59 vismodegib 59 BCX# 59 Virulizin ® 59 ThGRF 59 radezolid 59 telomerase therapeutic 59 LEUKINE 59 OMNARIS Nasal Spray 59 ozarelix 59 Phase 2a trial 59 TKM PLK1 59 tiapamil 59 esophageal candidiasis 59 Carfilzomib 59 cMET 59 tasocitinib 59 novel oral anticoagulant 59 Nanobody 59 romidepsin 59 liprotamase 59 motesanib 59 Factor Xa inhibitor 59 pomalidomide 59 squalamine 59 Plicera 59 DCVax ® Brain 59 orBec R 59 VersaFilm 59 cilengitide 59 epothilones 59 vorinostat 59 MGd 59 Azedra TM Onalta TM 59 demonstrated antitumor activity 59 Ceflatonin 59 MBP# [001] 59 Velcade bortezomib 59 MDS AML 59 EGFR inhibitors 59 histone deacetylase HDAC inhibitor 59 APTIMA HPV assay 59 Ixempra 59 ACZ# 59 mGluR5 NAM 59 Neo Kidney Augment 59 Litx 59 OMAPRO 59 Curaxin 59 Iluvien TM 59 Cethromycin 59 iclaprim 59 non metastatic osteosarcoma 59 Lenocta 59 ICA # 59 Talabostat 59 paclitaxel Taxol ® 59 Vidofludimus 59 next generation URAT1 59 Diamyd R 59 everolimus eluting stents 59 telaprevir VX 59 SILENOR 59 Xyfid TM 59 TRISENOX ® 59 Azedra ™ 59 Bioral ® 59 OMP #M# 59 kidney urologic 59 humanised monoclonal antibody 59 Viramidine 59 imatinib Gleevec ® 59 sunitinib malate 59 malignant ascites 59 Daclizumab 59 bortezomib Velcade 59 drug ISA# 59 metastatic HRPC 59 hematological indications 59 TLR agonists 59 Meets Primary Endpoint 59 omega interferon 59 Aeroquin 59 GRN#L 59 Myocet 59 Phase Ib II 59 TRAIL receptor antibodies 59 Nexavar ® 59 iniparib 59 colorectal cancer liver metastases 59 IAP inhibitor 59 VEGF inhibitor 59 MyVax personalized immunotherapy 59 TRISENOX 59 Perforomist ™ Inhalation Solution 59 CTAP# Capsules 59 SNALP technology 59 antimetabolite 59 Lovaxin C 59 Lisofylline 59 multi kinase inhibitor 59 IV Busulfex 59 briakinumab 59 sJIA 59 Symadex 59 Vitaxin 59 Aclidinium 59 vinca alkaloid 59 lintuzumab SGN 59 AMPK activators 59 phase Ib 59 recurrent metastatic ovarian cancer 59 EGS# 59 MYDICAR 59 anti EGFR antibody 59 anticancer therapies 59 Diabetic Macular Edema 59 ARIKACE ™ 59 brostallicin 59 Phase #b/#a trial 59 Ozarelix 59 teriflunomide 59 TBC# 59 Onalta 59 NEUGENE 59 anti angiogenic drugs 59 metastatic hormone refractory 59 Xelox 59 Erlotinib 59 VEGF receptor inhibitor 59 Vascugel 59 eniluracil 59 immune modulating 59 entinostat 59 INS# [001] 59 pegylated interferons 59 sapacitabine CYC# 59 Aviptadil 59 metastatic bladder 59 canagliflozin 59 Behcet uveitis 59 GOUT 59 rindopepimut 59 adecatumumab 59 Elagolix 59 selective orally bioavailable 59 THR beta agonist 59 sitaxsentan 59 Immunotherapeutic 59 advanced carcinoid 59 Deforolimus 59 L MTP PE 59 DU #b 59 torsemide ER 59 TTF Therapy 59 metastatic castration resistant 59 defensin mimetic antibiotic 59 Oral NKTR 59 TREANDA 59 Cleviprex TM clevidipine 59 APTIVUS 59 Aztreonam lysine 59 phase IIb trial 59 Tykerb lapatinib 59 fluoropyrimidine 59 interferon ribavirin 59 Inhalation Solution 59 Topical Interferon Alpha 2b 59 Tasimelteon 59 Radezolid 59 targeted radiotherapeutic 59 Vicinium TM 59 pafuramidine maleate 59 MAXY alpha 59 VEGF Trap 59 sumatriptan DosePro 59 Trofex TM 59 isoform selective 59 pharmacokinetic PK study 59 LY# [003] 59 viral kinetics 59 LymphoStat B TM 59 DURIN TM 59 INVEGA ® 59 ocular formulation 59 castration resistant prostate cancer 59 treat dysmenorrhea 59 NSABP C 59 REP# 59 TransVax tm 59 tipranavir 59 Zavesca r 59 CD# CEA 59 PEG PAL 59 concurrent chemoradiation 59 ALN VSP 59 diarrhea predominant irritable 59 AAG geldanamycin analog 59 Peginterferon alfa 2b 59 stable nucleic acid 59 lenalidomide dexamethasone 59 Zevalin consolidation 59 MKC# PP 59 hematological cancers 59 metastatic CRC 59 castrate resistant prostate cancer 59 Exherin TM 59 Genasense ® oblimersen 59 imexon 59 Metastatic Melanoma 59 Civacir 59 Resten NG 59 Phase III Pivotal 59 cleavable linker 59 VAPRISOL 59 Valortim R 59 Solulin 59 ARIKACE 59 mTOR kinase 59 LymphoStat B belimumab 59 glatiramer 59 Glufosfamide 59 cardiotoxic 59 opioid induced constipation OIC 59 brivaracetam 59 monoclonal antibody conjugated 59 afamelanotide 59 BAL# [002] 59 ularitide 59 OvaRex 59 severe gastroparesis 59 noscapine 59 MAb 59 JAK2 inhibitors 58 RSD# 58 TACI Ig 58 TRANSDUR Sufentanil 58 HepaGam B 58 Tolvaptan 58 human IgG1 monoclonal 58 Aryplase 58 palifosfamide 58 Hsp# Inhibitor 58 Ecallantide 58 aerosolized KL4 surfactant 58 Adlea 58 valopicitabine 58 plasma kallikrein inhibitor 58 platelet inhibitor 58 triphendiol 58 uric acid lowering 58 Zolinza 58 candidate XP# 58 immunostimulant patch 58 panitumumab Vectibix 58 StemEx 58 steroid refractory GvHD 58 optimal dosing 58 glufosfamide 58 DermaVir Patch 58 galiximab 58 Rezular 58 Phase Ib clinical 58 ZYBRESTAT 58 regorafenib 58 Q#IR 58 deferiprone 58 apremilast 58 Phase #b/#a 58 oral taxane 58 T Pred 58 Junovan 58 Pertuzumab 58 PNT# 58 Mitoxantrone 58 metastatic malignant melanoma 58 vosaroxin 58 sunitinib Sutent 58 aflibercept 58 TransVax 58 PEG Interferon lambda 58 PRTX 58 limiting toxicity 58 TriRima 58 canakinumab 58 Tarvacin Anti Cancer 58 Alnylam #x# 58 ThermoDox R 58 EVIZON TM 58 CRLX# 58 ganaxolone 58 Cimzia TM 58 EOquin TM 58 ADAGIO study 58 Prosaptide 58 zileuton IV 58 radiolabeled TM# 58 Itopride 58 retinal vein occlusion induced 58 Allovectin 7 r 58 ISF# 58 CMV vaccine 58 MDV# 58 HuMax CD# 58 Hedgehog Pathway Inhibitor 58 KSP inhibitor 58 vinorelbine 58 ARRY # 58 menadione 58 ANYARA 58 OMP #R# 58 cutaneous T 58 ASONEP 58 GAMMAGARD 58 PREZISTA r 58 Anturol 58 tiuxetan 58 MET inhibitor 58 IL-#/# 58 PI3 kinase inhibitors 58 registrational trial 58 cetuximab Erbitux 58 ADVEXIN p# therapy 58 isavuconazole 58 antiangiogenic therapy 58 iGVHD 58 TKB# 58 Fludara ® 58 LEVADEX TM 58 targeting CD# 58 Leukine ® 58 Gefitinib 58 Marqibo 58 MYLOTARG 58 rBChE 58 angiogenesis inhibitor 58 oral rivaroxaban 58 systemic fungal infections 58 ImmunoVEX HSV2 58 Chrysalin 58 thalidomide Thalomid 58 unique alkylating agent 58 eosinophilic asthma 58 opioid induced bowel dysfunction 58 oral FTY# 58 Canvaxin TM 58 ALV# 58 hormone refractory 58 standard chemotherapy regimen 58 PEGPH# 58 Phase 1b 58 bafetinib 58 Clolar ® 58 ToGA 58 Phase Ib IIa 58 selective modulator 58 Nicole Onetto MD 58 tafamidis 58 Linaclotide 58 Omacetaxine 58 urocortin 2 58 Ticagrelor 58 Vilazodone 58 TPI ASM8 58 Darinaparsin 58 SPARLON 58 Ramoplanin 58 rasagiline tablets 58 Canvaxin 58 pan HDAC inhibitor 58 Cinquil 58 candidate TNFerade biologic 58 Phase IIIb clinical 58 Alessandro Riva 58 delta isoform 58 nanoviricide 58 siRNA therapeutic 58 Zelrix 58 MYDICAR ® 58 injectable formulation 58 Atu# 58 Corlux 58 recurrent glioma 58 anti angiogenic therapy 58 posaconazole 58 Phase IIB 58 SUCCEED trial 58 Enzastaurin 58 randomized Phase IIb 58 AZX# 58 ReN# 58 preventing restenosis 58 Vidaza azacitidine 58 MYCAMINE 58 Chimigen TM 58 Epothilones 58 EndoTAG TM 58 oxybutynin ATD TM 58 Besivance 58 highly selective inhibitor 58 therapeutic regimens 58 liposomal doxorubicin 58 LibiGel ® 58 RAPAFLO 58 PSMA ADC 58 MPS IVA 58 ZFP Therapeutic 58 injectable formulations 58 Ataluren 58 decitabine 58 CDP# 58 chemotherapeutic 58 MEK inhibitor 58 polymerase inhibitors 58 Optiquel ™ 58 torezolid 58 histone deacetylase inhibitor 58 CRD5 58 skeletal metastases 58 BRIM2 58 lenalidomide Revlimid R 58 Phase IIb III 58 Unit Dose Budesonide 58 recombinant factor VIIa 58 Certolizumab pegol 58 rPA anthrax vaccine 58 Laquinimod 58 Cetrorelix 58 Vandetanib 58 Alzhemed TM 58 methylnaltrexone bromide 58 refractory angina 58 Pemetrexed 58 AZILECT R 58 Neo Urinary Conduit 58 cancer neuroendocrine tumor 58 Phase 1b clinical trials 58 Excellagen 58 anidulafungin 58 PREOS R 58 Tovaxin TM 58 Augment Injectable 58 relapsed ovarian cancer 58 Pivotal Phase III 58 Zalypsis 58 rALLy 58 vascular disrupting agents 58 Protexia R 58 prostate cancer CRPC 58 Angiocept 58 TRX1 58 Avanafil 58 tigecycline